Phathom Pharmaceuticals (NASDAQ:PHAT) is a biopharmaceutical company engaged in the development and commercialization of novel treatments for gastrointestinal diseases and disorders. The company focuses on creating better therapeutic options for patients suffering from conditions such as gastroesophageal reflux disease (GERD) and other related gastrointestinal (GI) diseases. Phathom Pharmaceuticals has been working on a portfolio of innovative drug candidates, including its lead project, a novel potassium-competitive acid blocker designed to provide an improved treatment alternative for acid-related disorders. With a dedicated team and a clear vision, the company aims to transform the current treatment landscape by addressing unmet medical needs and enhancing patient care in the GI therapeutic area.